Tocolytic therapy with ␤-adrenergic receptor agonists is a standard regimen to prevent preterm birth. Agonist exposure of ␤-adrenergic receptors causes receptor desensitization in other organs, and this may limit the therapeutic value of ␤-adrenergic receptor agonists. To study the effects of prolonged ␤-adrenergic agonist treatment in human myometrium, we obtained biopsies during Caesarean section of 14 pregnant patients who had received fenoterol for at least 5 days and 14 untreated pregnant controls. The densities of total ␤-adrenergic receptors, which are mainly of the ␤ 2 -subtype as assessed by [ 125 I]iodo-cyanopindolol binding in crude membrane fractions, were more than 50% smaller in women receiving fenoterol, whereas ␣ 2 -adrenergic receptor densities were similar. G s and G i G-protein ␣-subunit densities were unaltered as assessed by Western blotting and pertussis toxin-catalyzed [ 32 P]ADP-ribosylation. ␤-Adrenergic receptor kinase (␤ARK) activity, as determined using bovine rhodopsin as the substrate, was the same in the two groups. Adenylyl cyclase activities in the presence of guanine nucleotides, NaF, forskolin, or Mn ϩϩ were also not altered by fenoterol treatment. The messenger RNA (mRNA) concentrations of ␤ 2 -adrenergic receptors, ␤ARK-I and glyceraldehyde-3-phosphate dehydrogenase (as a reference), as determined by quantitative PCR, were unaffected by fenoterol treatment. We conclude that tocolysis with fenoterol results in a selective down-regulation of myometrial ␤-adrenergic receptors, which is not associated with a reduction in the respective mRNA concentrations or alterations of ␣ 2 -adrenergic receptors, G s and G i ␣-subunits, or ␤ARK activity or mRNA. (J Clin Endocrinol Metab 82: 1235-1242, 1997) P RETERM labor is commonly treated with long-term application of ␤-adrenergic receptor agonists to produce myometrial relaxation and prevent or delay preterm birth. However, the long-term efficacy and therapeutic usefulness of this approach have been repeatedly questioned (1). For example, the Canadian preterm investigators group (2) reported results of a large study indicating that treatment with the ␤-adrenergic agonist, ritodrine, had no long-term benefits, produced no significant difference in the delay of delivery, and did not affect neonatal morbidity. Although this study has been criticized because of alleged underdosage of ritodrine (3, 4), and even though another large study reported beneficial effects of long-term tocolysis with iv terbutaline (5), these data raise the possibility that the usefulness of ␤-adrenergic agonists in tocolysis may be limited.
I]iodo-cyanopindolol binding in crude membrane fractions, were more than 50% smaller in women receiving fenoterol, whereas ␣ 2 -adrenergic receptor densities were similar. G s and G i G-protein ␣-subunit densities were unaltered as assessed by Western blotting and pertussis toxin-catalyzed [ 32 P]ADP-ribosylation. ␤-Adrenergic receptor kinase (␤ARK) activity, as determined using bovine rhodopsin as the substrate, was the same in the two groups. Adenylyl cyclase activities in the presence of guanine nucleotides, NaF, forskolin, or Mn ϩϩ were also not altered by fenoterol treatment. The messenger RNA (mRNA) concentrations of ␤ 2 -adrenergic receptors, ␤ARK-I and glyceraldehyde-3-phosphate dehydrogenase (as a reference), as determined by quantitative PCR, were unaffected by fenoterol treatment. We conclude that tocolysis with fenoterol results in a selective down-regulation of myometrial ␤-adrenergic receptors, which is not associated with a reduction in the respective mRNA concentrations or alterations of ␣ 2 -adrenergic receptors, G s and G i ␣-subunits, or ␤ARK activity or mRNA. (J Clin Endocrinol Metab 82: 1235-1242, 1997) P RETERM labor is commonly treated with long-term application of ␤-adrenergic receptor agonists to produce myometrial relaxation and prevent or delay preterm birth. However, the long-term efficacy and therapeutic usefulness of this approach have been repeatedly questioned (1) . For example, the Canadian preterm investigators group (2) reported results of a large study indicating that treatment with the ␤-adrenergic agonist, ritodrine, had no long-term benefits, produced no significant difference in the delay of delivery, and did not affect neonatal morbidity. Although this study has been criticized because of alleged underdosage of ritodrine (3, 4) , and even though another large study reported beneficial effects of long-term tocolysis with iv terbutaline (5) , these data raise the possibility that the usefulness of ␤-adrenergic agonists in tocolysis may be limited.
Agonist-stimulation of ␤-adrenergic receptors causes receptor desensitization in many cells and tissues (see Refs. 6 and 7 for reviews). Desensitization of agonist-stimulated ␤-adrenergic receptors has also been observed in the myometrium. Lye et al. (8) induced preterm labor in sheep with mifepristone (RU486) and observed that iv ritodrine initially inhibited labor contractions but lost its effects within 16 h. This loss of efficacy was accompanied by a reduced cAMPresponse to ␤-adrenergic receptor stimulation and by reduced densities of ␤-adrenergic receptors in the myometria. Other studies have also observed desensitization of myometrial ␤-adrenergic receptors in sheep on prolonged agonist infusion (9, 10) . In the human myometrium, ␤-adrenergic receptor agonists have been shown to reduce the number of ␤-adrenergic receptors, which were mainly of the ␤ 2 -subtype (11, 12) . However, nothing is known about the underlying mechanisms leading to this decrease in receptor number in the myometrium.
␤-Adrenergic receptor desensitization can occur by multiple biochemical mechanisms. The two most important mechanisms are the rapid uncoupling between receptors and their G-proteins caused by phosphorylation of the receptors by the ␤-adrenergic receptor kinases (␤ARK) (13), followed by binding of the inhibitor protein ␤-arrestin (14) , and the much slower reduction of the receptor number (down-regulation) that evolves over many hours (15) . When the different isoforms of ␤-adrenergic receptors are expressed in identical cell lines, these desensitization mechanisms are most pronounced for the ␤ 2 -subtype, less pronounced for the ␤ 1 -subtype, and largely nonexistent for the ␤ 3 -subtype (16, 17) .
The present study was undertaken to investigate the alterations that tocolysis might cause in the myometrial ␤-ad-renergic receptor system, including not only the receptors themselves, but also the ␤-adrenergic receptor kinase and the stimulatory and inhibitory G-proteins as well as the G i -protein coupled ␣ 2 -adrenergic receptors. We report that a reduction of the ␤ 2 -adrenergic receptor number, without a concomitant reduction of the corresponding messenger RNA (mRNA), is the only alteration found in response to longterm tocolysis with fenoterol.
Subjects and Methods

Patients and biopsy procurement
We studied myometrial biopsies obtained from 28 patients during Caesarean section after at least 5 days of fenoterol administration (n ϭ 14) or from untreated control patients (n ϭ 14). The studies had been approved by the ethical committee of the medical faculty, and all patients gave informed written consent. The clinical data of these patients are given in Table 1 . All patients in the fenoterol group received fenoterol at the indicated doses, and all but one received MgSO 4 to enhance tocolytic effects, and metoprolol to block ␤ 1 -adrenergic receptors. None of the patients from the control group received catecholamines or ␤-adrenergic receptor antagonists. The average gestational age was 4 weeks higher in the control group because for ethical reasons tocolytic treatment was given to all women of low gestational age. Myometrial specimens of 0.5-3 g were removed from the free wall of the uterus at the time of the Caesarean section and placed in liquid nitrogen immediately after removal and stored at Ϫ80 C. Tissue procurement was the same for all biopsies. Unfortunately, the amount of available tissue did not allow to quantify each parameter in all patients.
Receptor binding studies
Crude membrane fractions were prepared from a fraction of the frozen tissue samples as previously described (12, 18) . Briefly, a piece of frozen tissue was thawed and homogenized with an Ultra-Turrax (Janke & Kunkel, Staufen, Germany) in ice-cold buffer (0.25 m sucrose, 5 mm Tris-HCl, 1 mm EDTA, pH 7.4). The homogenate was centrifuged at 600 ϫ g for 15 min, the supernatant filtered through four layers of medical gauze, and centrifuged at 50,000 ϫ g for 20 min at 4 C. The resulting pellets were resuspended in 10 mm Tris-HCl, 154 mm NaCl buffer, p.H 7.4, that contained 0.55 mm ascorbic acid to yield a protein concentration of 0.5-1 mg/mL (for ␤-adrenergic receptor assessment) or in 50 mm Tris-HCl, 0.5 mm EDTA buffer, pH 7.4, to yield a protein concentration of 2-3 mg/mL (for ␣ 2 -adrenergic receptor assessment). The protein concentration was assessed by the method of Bradford (19) using bovine immunoglobulin G as standard. 
Quantification of G-protein ␣-subunits
G-protein ␣-subunits were quantified by immunoblotting and pertussis toxin-catalyzed ADP-ribosylation as previously described in detail (20) . Briefly, ␣-subunits of G s and G i were detected using the antisera RM/1 and AS/7 (New England Nuclear), respectively, at a 1:500 dilution, followed by quantitation on the blots with [
125 I]-protein A (SA 8.5 
Determination of ␤ARK activity
Enzymatic activity of ␤ARK was measured as previously described (21, 22) . Frozen myometrial tissue (100 mg) was homogenized for 30 sec with a polytron device in 1 mL 20 mm Tris-HCl, pH 7.5, 2 mm EDTA, and centrifuged for 10 min at 200,000 ϫ g. The protein concentration in the supernatants was determined according to Bradford (19) . Ureatreated rod outer segments containing Ͼ95% rhodopsin were prepared from bovine retinae as the substrate for ␤ARK. Aliquots (50 g protein) of these cytosolic preparations were incubated with 500 pmol rhodopsin in the same buffer containing 10 mm MgCl 2 and 0.3 mm [
32 P]ATP in a total volume of 60 L.
32 P incorporation into rhodopsin was determined by separation of the reaction mixture by SDS-PAGE and quantitation of the radioactivity in the rhodopsin band with a phosphoimager (Fuji, Tokyo, Japan).
Determination of mRNA concentrations
RNA from the frozen tissue samples was prepared by a shortened version of the protocol of Chomczinski and Sacchi (23) essentially as recently described (24, 25) . The purity of the RNA was checked by measuring the ratio of the absorbance at 260 and 280 nm and was 1.8 -2.0 in all cases. Aliquots (500 ng) of RNA were reverse transcribed into complementary DNA (cDNA) using random hexamers and Superscript II reverse transcriptase (GIBCO/BRL, Gaithersburg, MD) as described elsewhere (24) . In all experiments, reactions containing no reverse transcriptase were done as negative controls.
Sense and antisense oligonucleotide primer pairs were synthesized to match the sequences of the human ␤ 2 -adrenergic receptor (26) , human ␤ARK-I (21) and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH (27) . Details about the primers and the expected PCR products are given in Table 2 . PCR was done with the transcript obtained from 50 ng RNA using 0.5 m of the respective primers, 1. Table 2 , and an extension at 72 C for 1 min (10 min in last cycle). Multiple samples from different biopsies were assayed for each gene using a single master reaction mixture. The PCR products were isolated by electrophoresis on a 10% polyacrylamide gel. After drying on a gel dryer, the incorporated radioactivity was determined using a phosphoimager (Fuji).
In all experiments, a template-free negative control, RNA template not subjected to RT, and known amounts of plasmids containing the respective sequences were amplified to monitor the accuracy and efficiency of the PCR. Validation of this PCR technique in comparison with a solution hybridization assay was recently published from our laboratory (25) ; moreover, we have found a tight linear correlation between ␤ 2 -adrenergic receptor mRNA concentrations as assessed by this PCR method and Northern blotting in DDT 1 -MF2 smooth muscle cells (r ϭ 0.997, n ϭ 8, data not shown).
Adenylyl cyclase assays
Adenylyl cyclase activity was assessed as described by Salomon et al. (28) with minor modifications as detailed elsewhere (29) . Two different incubation conditions were employed. For Gpp(NH)p, NaF, and forskolin activation, membranes (30 - 
Statistical analysis
Data are expressed as mean Ϯ sem. Comparison between the two different groups was performed by two-tailed unpaired t tests. A P value Ͻ0.05 was considered significant.
Results
Down-regulation of ␤ 2 -adrenergic receptors by tocolysis
The high-affinity antagonist radioligand ICYP was used to quantitate ␤-adrenergic receptors in human myometrial membranes, 85.5% of which are of the ␤ 2 -subtype (12) . The number of binding sites for ICYP was 6.3 Ϯ 0.6 fmol/mg protein in the control group but only 2.8 Ϯ 0.4 fmol/mg protein in patients who had been treated with fenoterol (P Ͻ 0.01, Fig. 1A ). On the other hand, ␤-adrenergic receptor number in the control and in the tocolysis group was not significantly related to the gestational age (r 2 0.2344 and 0.0497, respectively; P Ͼ 0.05 in both groups; Fig. 1B ). The number of ␣ 2 -adrenergic receptors was not significantly changed in the fenoterol treatment group (Fig. 1A) .
G-protein studies
G s and G i ␣-subunits were assayed by quantitative Western blotting using the RM/1 or AS/7 antiserum, respectively, in conjunction with [ 125 I]-protein A detection. The densities of both classes of ␣-subunits were unaffected by fenoterol treatment (Table 3) . Likewise, the concentration of substrates for pertussis toxin-catalyzed ADP-ribosylation, which corresponds to the ␣-subunits of the G o /G i -family, were not different between the two groups of patients (Table 3) . These results indicate that G-protein densities in human myometrium were not affected by tocolytic treatment.
To test whether the functional activity of G s and/or G i Fig. 2 , Gpp(NH)p-, NaF-, forskolin-, and Mn ϩϩ -induced adenylyl cyclase activation was not affected by fenoterol treatment, indicating that the functional activities of G s , G i , and the catalytic unit of adenylyl cyclase were not altered.
␤ARK activity
To test whether the ␤-adrenergic receptor down-regulation is [as in heart failure (24, 33)], accompanied by increased ␤ARK expression, we measured the total ␤ARK activity in cytosolic preparations from the myometria. These assays were done using rhodopsin as the substrate, which can be phosphorylated not only by the predominant kinase, ␤ARK-I, but also by the other related members of this kinase family (13) . Rhodopsin phosphorylation was readily obtained with cytosolic preparations from both control and fenoterol-treated patients (Fig. 3, inset) . Quantitative analysis of these assays revealed almost identical activities in the two groups of patients (Fig. 3) .
Quantification of mRNAs
To determine the steady state concentrations of the mRNAs for the ␤ 2 -adrenergic receptor and also for ␤ARK-I, quantitative RT-PCR were carried out with RNA prepared from human myometria. GAPDH, a housekeeping gene widely used for standardization in such experiments, was chosen as an endogenous control. The absolute values of the expression of GAPDH in these biopsies were very similar in both groups (data not shown). In agreement with our earlier data on myocardium (24, 25, 33) , this indicates that this mRNA is not affected by ␤-adrenergic stimulation and can therefore be used for normalization. Figure 4A shows the PCR products obtained for the ␤ 2 -adrenergic receptor, GAPDH, and ␤ARK-I. In all cases, a single well-defined product of the appropriate size was obtained, which could be used for quantification by phosphoimaging. Such quantifications are shown in Fig. 4B 3 H]rauwolscine were: control, 0.72 Ϯ 0.11 nM (n ϭ 13); tocolysis, 0.89 Ϯ 0.09 nM (n ϭ 13). **, P Ͻ 0.01 vs. control. B, Relationship between ␤-adrenergic receptor density in myometrial membranes and gestational age in fenoterol-treated (Ⅲ) and nontreated pregnant women (E). For details see Patients and Methods. Ordinate: myometrial ␤-adrenergic receptor density in femtomoles ICYP specifically bound per milligrams protein; abscissa: gestational age of patients in weeks. for GAPDH. The efficiencies of amplification were almost identical, which allows the use of the GAPDH-product for normalization. All biopsies were then screened simultaneously for the expression of the specific mRNAs. As expected from the activity measurements, the amounts of ␤ARK-I mRNA were the same in both groups (Fig. 5) . Likewise, in spite of the marked reduction of the ␤ 2 -adrenergic receptor expression, fenoterol treatment had no effect on their mRNA (Fig. 5) . This suggests that the down-regulation of the receptors occurs on the protein rather than the mRNA concentration.
Discussion
Over the past years it has become clear that G-proteincoupled receptors are part of a complex and highly regulated signal transduction machinery. Although this appears to be important to maintain a physiological balance, such regulation may limit the therapeutic potential of receptor agonists as drugs. In fact, the effects of many receptor agonists vane over time. In the case of the ␤-adrenergic receptors, the molecular mechanisms of this regulation have been studied in much detail in cultured cells (for recent reviews see Refs. 6 and 7). In addition, a large number of studies have addressed the regulation of these receptors in the human heart in chronic heart failure (34) . Heart failure is characterized by enhanced sympathetic activity (35) leading to increased stimulation of these receptors, and this has been shown to cause a loss of responsiveness of the heart to the stimulatory effects of catecholamines (36) . This loss of responsiveness has been traced back to reduced mRNA-concentrations of the ␤ 1 -adrenergic receptors (24, 37, 38) , which represent the predominant subtype in the heart, and to increased concentrations of ␤ARK-I mRNA (33) , which lead to increased concentrations of this kinase and thus presumably to uncoupling of receptors and G-proteins. Interestingly, however, mRNA concentrations of cardiac ␤ 2 -adrenergic receptors were unchanged in chronic heart failure (24, 37, 38) , despite the fact that some studies have found a decrease in their number (for references see Ref. 39) . Another biochemical event that can contribute to a loss of ␤-adrenergic receptor responsiveness is the upregulation of inhibitory elements in the signal transduction cascade, i.e. G i -protein or receptors coupled to it (cross-regulation, see Refs. 40 and 41). Thus, chronic activation of cardiac ␤-adrenergic receptors is accompanied by an increase in the inhibitory G-protein G i in human heart failure (42) and in rats following chronic infusion of isoprenaline (43, 44) .
The present study was undertaken with the hypothesis FIG. 3 . Effects of tocolysis with fenoterol on myometrial ␤ARK activity. Cytosolic preparations from myometrial specimens were assayed for their ability to phosphorylate ␤ARK-substrate rhodopsin in a light-dependent manner, and rhodopsin phosphorylation was visualized by SDS-PAGE and autoradiography (inset). Extent of phosphate incorporation was quantified with a phosphoimager. Data are mean Ϯ SEM.
FIG. 4. PCR amplification of cDNAs for ␤ 2 -adrenergic receptor (␤ 2 AR), GAPDH, and ␤ARK-I. PCRs were done with cDNA transcribed with random hexamers from 50 ng of total RNA. A, PCR products obtained after 30, 23, and 32 cycles, respectively. B, Amplification characteristics. After indicated number of cycles, 10-L aliquots were taken from reaction mixture and subjected to polyacrylamide gel electrophoresis followed by autoradiography. [ 32 P]Deoxycytidine triphosphate incorporation was used to quantify PCR products using a phosphoimager. Amplification efficiencies are given for the different PCR products. Data are presented as mean Ϯ SEM from four different PCR reactions.
that chronic activation of myometrial ␤ 2 -adrenergic receptors with ␤ 2 -adrenergic receptor agonists might cause similar changes as those observed for cardiac ␤ 1 -adrenergic receptors in chronic heart failure, and that the ensuing desensitization of the ␤ 2 -adrenergic receptor system might be a reason for the limited usefulness of this tocolytic therapeutic regimen. According to standard medical practice in Germany, it is not considered acceptable to withhold ␤ 2 -adrenergic agonist treatment in women in preterm labor. Moreover, a ␤ 1 -selective antagonist (e.g. metoprolol) and MgSO 4 are added regularly to minimize concomitant stimulation of cardiac ␤ 1 -adrenoceptors and to enhance tocolytic efficacy, respectively. Therefore, the women receiving the ␤ 2 -adrenergic agonist differ from the control patients of our study in three additional ways, i.e. gestational age, metoprolol treatment, and MgSO 4 treatment. Although we cannot rule out that any of these additional factors has affected the outcome of our study, we feel that the fenoterol treatment had the dominant effect for the following reasons: to our knowledge MgSO 4 has never been shown to affect ␤-adrenergic receptor function or desensitization, and no mechanism to this effect is known. Although treatment with ␤ 1 -selective antagonists such as metoprolol can up-regulate ␤ 1 -adrenergic receptors, the density of ␤ 2 -adrenergic receptors was not affected in such studies (45) . A more serious problem is whether different gestational ages might have contributed to the observed data in our study. For example, it has been observed that human myometrial ␤-adrenergic receptors undergo functional uncoupling towards the end of pregnancy, i.e. in gestational weeks 39 -40 (46) . However, we feel that this cannot explain the reduction of ␤-adrenergic receptors seen in our study for several reasons. First, gestational age and myometrial ␤-adrenergic receptor density were not significantly correlated within the control or tocolysis group. Second, ␤-adrenergic receptor density was also lower in the tocolysis group in the subset of patients with similar gestational ages in both groups (cf. Fig. 1B) . Third, the data by Litime et al. (46) imply functional uncoupling towards the end of pregnancy, which, if anything, would result in an understimation of the desensitization in tocolysis patients with a smaller gestational age compared with control term women. Therefore, it appears that the ␤ 2 -adrenergic agonist treatment indeed is the most likely cause of our observations. Confirmation in a study design with random allocation of tocolytic treatment would be useful, but that is not considered ethically acceptable in Germany.
The overall pattern of changes in the present study was quite different from that observed for ␤ 1 -adrenergic receptors in heart failure: we found that tocolysis with fenoterol caused an isolated decrease of receptor densities, without a concomitant decrease of the corresponding mRNA. Neither the activity or mRNA concentration of ␤ARK-I nor the concentrations or functional activities of the relevant G-protein ␣-subunits were altered. Furthermore, we found no evidence for a cross-regulation of ␣ 2 -adrenergic receptors.
A possible reason for this discrepancy might lie in the fact that whereas heart failure develops over very long periods of time, tocolysis in our patients was only performed for days, and that the other changes observed in heart failure might appear only later. However, application of ␤-adrenergic receptor agonists to rats for 4 days has been reported to cause not only down-regulation of cardiac ␤-adrenergic receptors, but also receptor uncoupling as well as up-regulation of G i ␣-subunits (43, 44) . Furthermore, rapidly evolving experimental models of heart failure in dogs have been reported to decrease ␤-adrenergic receptor number und coupling, G s ␣-subunit expression, and adenylyl cyclase (for references see Ref. 34 ). Thus, the cardiac ␤-adrenergic receptor system of several species reacts to changes in ␤-adrenergic stimulation with an array of changes in a matter of days. This suggests that the different patterns of changes in the cardiac and myometrial ␤-adrenergic receptor systems are not caused by the relatively short duration of ␤-adrenergic receptor activation during tocolysis. On the other hand, similar to the myometrium (present study), we recently found that a 2-week treatment of healthy volunteers with the ␤ 2 -adrenergic receptor agonist terbutaline markedly reduced lymphocyte ␤ 2 -adrenergic receptor number but did not affect lymphocyte G i -densities (47) , and that treatment of the human neuroblastoma cell line, SK-N-MC, with isoprenaline for 24 h caused a marked decrease in ␤ 1 -adrenergic receptor number but did not change G i -densities (48) ; extending the incubation to 4 days also did not lead to any changes in G i (our unpublished observations).
A second possible explanation for these differences is that whereas the cardiac ␤-adrenergic receptors are mostly of the ␤ 1 -subtype (39), the ␤ 2 -subtype predominates in the myometrium (11, 12) . However, when expressed in the same cell line, the ␤ 2 -subtype has been shown to be more readily regulated than the ␤ 1 -subtype (16). Furthermore, cross-regulation between ␤-adrenergic receptors and G i ␣-subunits and ␣ 2 -adrenergic receptors has been demonstrated much better for the ␤ 2 -than for the ␤ 1 -subtype (49, 50). And finally, alterations in G i ␣-subunit expression are thought to be cAMP-mediated (42) , and both the ␤ 1 -and the ␤ 2 -subtype are coupled to increases in cAMP. Thus, there is no reason to assume that in a tissue expressing ␤ 2 -adrenergic receptors the regulatory response to ␤-receptor agonists would be more limited than in a tissue expressing the ␤ 1 -subtype.
Taken together, the most reasonable explanation for the different types of regulation of myometrial and myocardial ␤-adrenergic receptors is the hypothesis that there are tissue or organ-specific factors that determine the pattern of receptor desensitization. Such tissue-specific factors might be the expression of specific regulatory proteins, such as the receptor kinases, phosducins, or mRNA-regulatory proteins (51) (52) (53) .
It is interesting to note that tocolysis causes a reduction of myometrial ␤ 2 -adrenergic receptor densities without a concomitant reduction of the corresponding mRNA. In many studies on isolated cells, a similar time course for the agonistinduced down-regulation of ␤ 2 -adrenergic receptors and their mRNA has been observed, and this mRNA reduction has been suggested to be an essential mechanism of receptor down-regulation (54 -57) . This may indeed be true for cell culture lines, because a continuous synthesis is necessary to maintain receptor densities in a rapidly dividing cell population. However, in the tissues of intact animals, ␤-adrenergic receptors have a half-life of many days to several weeks (58) . Thus, reduced mRNA concentrations should not be able to induce substantial down-regulation of the receptors themselves in a matter of a few days (7) , and in fact, we did not even find any reduction in myometrial ␤ 2 -adrenergic receptor mRNA after tocolysis. The down-regulation of these receptors by tocolysis must therefore be caused by degradation of the receptors themselves.
In summary, our study indicates that tocolytic treatment with fenoterol caused only a single change in the myometrial ␤ 2 -adrenergic receptor system: an isolated down-regulation of the receptors that was most likely caused by direct degradation of the receptors. Comparison of these changes with those observed in the cardiac ␤-adrenergic receptor systems underlines the importance of tissue specific factors in receptor regulation. It appears likely that the down-regulation of myometrial ␤-adrenergic receptors limits the usefulness of ␤-adrenergic receptor agonists as tocolytic agents.
